Human Carcinoembryonic antigen-related cell adhesion molecule 5(CEA) Recombinant Protein

Description of Human Carcinoembryonic antigen-related cell adhesion molecule 5(CEA) Recombinant Protein

Human Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEA) Recombinant Protein: Structure, Activity, and Application

Introduction

Human Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEA) is a glycoprotein that belongs to the immunoglobulin superfamily. It is encoded by the CEA gene and is primarily expressed in the epithelial cells of the gastrointestinal tract, pancreas, and lungs. CEA is involved in cell-cell adhesion and plays a crucial role in cell signaling and tumor progression. The recombinant form of CEA (CEA Recombinant Protein) has been extensively studied for its structure, activity, and potential applications as a drug target.

Structure of CEA Recombinant Protein

CEA Recombinant Protein is a 180 kDa glycoprotein that consists of a single polypeptide chain with a large extracellular domain, a transmembrane region, and a short cytoplasmic tail. The extracellular domain is composed of five immunoglobulin-like domains (Ig-like domains) and a variable number of N-linked glycans. The Ig-like domains are responsible for the protein’s adhesion properties and are highly conserved among different species. The transmembrane region anchors the protein to the cell membrane, while the cytoplasmic tail is involved in intracellular signaling.

Activity of CEA Recombinant Protein

CEA Recombinant Protein plays a crucial role in cell adhesion, migration, and signaling. It interacts with other CEA family members, such as CEACAM1, CEACAM6, and CEACAM8, to form homophilic and heterophilic interactions. These interactions mediate cell-cell adhesion and promote cell migration during embryonic development and tissue repair. In addition, CEA Recombinant Protein has been shown to modulate the activity of various signaling pathways, including the PI3K/Akt and MAPK pathways, which are involved in cell proliferation and survival.

Application of CEA Recombinant Protein

Drug Target

CEA Recombinant Protein has been identified as a potential drug target for the treatment of various cancers, particularly colorectal cancer. The overexpression of CEA in cancer cells has been linked to tumor progression, metastasis, and resistance to chemotherapy. Therefore, targeting CEA with specific inhibitors or monoclonal antibodies can potentially inhibit tumor growth and improve patient outcomes.

Diagnostic Marker

CEA Recombinant Protein is commonly used as a diagnostic marker for the detection and monitoring of certain types of cancer, such as colorectal, pancreatic, and lung cancer. Elevated levels of CEA in the blood can indicate the presence of cancer, and monitoring CEA levels can help track the progression of the disease and response to treatment.

Immunotherapy

CEA Recombinant Protein has also been investigated as a potential target for cancer immunotherapy. Monoclonal antibodies targeting CEA have been developed and tested in clinical trials for the treatment of colorectal cancer. These antibodies can specifically bind to CEA on cancer cells and induce an immune response, leading to the destruction of cancer cells.

Biomaterials

The adhesion properties of CEA Recombinant Protein have also been utilized in the development of biomaterials for tissue engineering and regenerative medicine. CEA-based biomaterials have been shown to promote cell adhesion and proliferation, making them ideal for applications such as wound healing and tissue repair.

Conclusion

In summary, Human Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEA) Recombinant Protein is a glycoprotein with a complex structure and diverse functions. Its involvement in cell adhesion, migration, and signaling makes it a potential drug target for the treatment of cancer.